ArticlePharmaceutical research1999
A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo.
Article in Pharmaceutical research, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 65 citations in OpenAlex.
- One-Pot, One-Step Synthesis of Drug-Loaded Magnetic Multimicelle Aggregates.Bioconjugate chemistry · 2022Article
- Long-Circulation and Brain Targeted Isoliquiritigenin Micelle Nanoparticles: Formation, Characterization, Tissue Distribution, Pharmacokinetics and Effects for Ischemic Stroke.International journal of nanomedicine · 2022Article
- Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.Molecular pharmaceutics · 2013Article
- Structure and dynamics of highly PEG-ylated sterically stabilized micelles in aqueous media.Journal of the American Chemical Society · 2011Article
- Micellar nanomedicine of human neuropeptide Y.Nanomedicine : nanotechnology, biology, and medicine · 2011Article
- Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis.Pharmaceutical research · 2011Article
- Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer.Nanomedicine : nanotechnology, biology, and medicine · 2009Article
- Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders.Journal of cellular and molecular medicine · 2008Review
- Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles.International journal of pharmaceutics · 2008Article
- Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.Annals of the rheumatic diseases · 2007Review
- Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders.Peptides · 2007Review
- Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs.Pharmaceutical research · 2003Article
- Optimization of Landscape Phage Fusion Protein-Modified Polymeric PEG-PE Micelles for Improved Breast Cancer Cell Targeting.Journal of nanomedicine & nanotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeTo determine whether human vasoactive intestinal peptide (VIP)-poly(ethylene glycol) (PEG)-grafted distearoyl-phosphatidylethanolamine (DSPE) micelles elicit potent and stable vasodilation in vivo.
methodsPEG-DSPE micelles were prepared by co-precipitation. VIP was loaded into micelles by incubation at room temperature. Vasoactivity of VIP in SSM was determined by monitoring changes in diameter of resistance arterioles in the in situ hamster cheek pouch using intravital microscopy.
resultsVIP easily undergoes self-assembly into small PEG-DSPE micelles (mean [+/-SEM] size, 18+/-1 nm) in a time-dependent fashion. This generates a potent vasoactive matrix at nanomole concentrations of VIP as manifested by approximately 3-fold potentiation and prolongation of vasodilation relative to that evoked by aqueous VIP alone (p < 0.05). This response is specific and mediated by the L-arginine/nitric oxide (NO) biosynthetic pathway. Micellar VIP dispersion remains vasoactive for at least 14 days after preparation and storage at 4 degrees C.
conclusionsA novel, self-associated, small and stable PEG-DSPE micellar formulation of VIP amplifies vasodilation in the in situ peripheral microcirculation in a specific fashion by elaborating NO. An optimized formulation could be considered for certain cardiovascular disorders associated with L-arginine/NO biosynthetic pathway dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.